Weiguang Biological

Shenzhen Weiguang Biological Products is a leading Chinese biopharmaceutical company specializing in the research, development, and manufacturing of plasma-derived medicines. Founded in 1985 and headquartered in Shenzhen, the company is a state-controlled entity listed on the Shenzhen Stock Exchange and is now a subsidiary of Sinopharm. Its core product portfolio includes human albumin, intravenous immunoglobulin (IVIG), and specialized immunoglobulins for hepatitis B, rabies, and tetanus. Weiguang Biological operates a comprehensive network of plasma collection centers and maintains high-standard GMP manufacturing facilities. The company is strategically expanding its research into recombinant proteins and vaccines to complement its traditional blood product business. As a key player in China's healthcare sector, it provides critical therapies for immunology, hematology, and emergency medicine.